Given the current market conditions, a slowdown in private equity investment within the sector is to be expected. As such, the funding environment for the remainder of 2022 is likely to look much different than what we’ve seen in recent quarters. What that means for early-stage biotech startups is that raising a new round of funding over the next year could become much harder and take longer than expected.
